(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 15.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Apellis Pharmaceuticals's revenue in 2025 is $775,840,000.On average, 11 Wall Street analysts forecast APLS's revenue for 2025 to be $101,333,458,723, with the lowest APLS revenue forecast at $92,891,758,366, and the highest APLS revenue forecast at $112,983,324,450. On average, 10 Wall Street analysts forecast APLS's revenue for 2026 to be $126,195,420,668, with the lowest APLS revenue forecast at $108,803,132,482, and the highest APLS revenue forecast at $151,585,373,786.
In 2027, APLS is forecast to generate $151,371,336,897 in revenue, with the lowest revenue forecast at $131,086,597,180 and the highest revenue forecast at $165,470,749,871.